Inamed To Spurn Medicis? Aesthetics Firm Weighs Allergan’s $3.2 Bil. Offer
This article was originally published in The Gray Sheet
Executive Summary
Inamed is considering a $3.2 bil. unsolicited offer from pharmaceutical specialty firm Allergan after determining that the bid is likely superior to its planned merger with Medicis, the firm announced Nov. 16
You may also be interested in...
Inamed’s Board Embraces Allergan’s Offer After Dissolving Deal With Medicis
Inamed's board unanimously approved a proposed plan to merge with Allergan for $3.2 bil. on Dec. 15, two days after rejecting Medicis' $2.8 bil. acquisition offer
Candela Sees Beaming Future In Family Practice As Stock Jumps 54%
Candela's improved access to the emerging family practice aesthetic market through an exclusive distribution deal with McKesson sparked investor interest in the aesthetic laser firm in November
Inamed’s Board Embraces Allergan’s Offer After Dissolving Deal With Medicis
Inamed's board unanimously approved a proposed plan to merge with Allergan for $3.2 bil. on Dec. 15, two days after rejecting Medicis' $2.8 bil. acquisition offer